TickerTalks
Browse all tickers →
TickerTalks›$KOD
KOKOD

Kodiak Sciences Inc.

$KOD·$6.2B·Biotechnology·Healthcare
$81.09-11.5%YTD+228.3%1Y+549.8%
Price updated 5h ago·X counts updated 3d ago
KOKOD
$KODKodiak Sciences Inc.
$81.09-11.50%213 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $KOD on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

213X posts · last 7 days
Sep 28Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $KOD's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $KOD — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventAcceleratingAI verdict · as of 2026-10-02

The move is getting stronger, with heavier trading behind it.

Retina-therapy biotech up 525% trailing-12m after Phase 3 DAYBREAK study met primary endpoints for Zenkuda and tabirafusp-ted in wet AMD.

Kodiak Sciences develops Antibody Biopolymer Conjugate therapies for retinal diseases — tarcocimab tedromer (Zenkuda) and tabirafusp-ted (KSI-501) in wet age-related macular degeneration — with the Phase 3 readout the critical de-risking event.

  • Pre-revenue through Q1 FY26 (zero revenue, operating losses $0.94-1.16 per share)
  • TTM: -8.3x earnings (negative), -254% ROE, FCF yield -9.0%, debt-to-equity 0.50 — standard clinical-stage economics
  • 2026 estimate: $11.3M revenue, -$3.74 EPS; 2027 $45.9M, -$3.12 EPS — modeling launch beginning in 2027
  • YTD +253%, trailing-12m +525% at $98.46 against a $2.84B market cap — the equity has moved from $32 to $90 in a day on the Phase 3 readout
  • Sep 28: Phase 3 DAYBREAK study met primary endpoints for both Zenkuda and KSI-501 in wet AMD — BLA filing nears
  • Director Bros. Advisors (Baker) acquired 33,726 additional shares — specialist bio-dedicated fund adding

The Phase 3 positive readout changes the thesis from binary trial risk to launch-execution risk. The equity has priced in the de-risking; the next leg is BLA-filing timing and wet-AMD market share capture, with the 2027 estimates implying a modest launch ramp.

What to watch: Nov 12 Q3 earnings and BLA filing-timeline disclosure — whether the regulatory submission lands on a timeline that supports the 2027 revenue estimates.

On the calendar: 2026-11-12 Q3 earnings

Read the AI verdict on $KOD

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops novel bispecific anti-VEGF antibodies for retinal diseases including wet AMD and diabetic macular edema.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $KOD.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $KOD

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+34.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-87.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-9.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-254%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.5Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$-1.05$-0.96-9.8%
Q1 2026May 7, 2026$-0.94$-0.93-1.1%
Q4 2025Mar 31, 2026$-1.04$-1.02-2.0%
Q3 2025Nov 13, 2025$-1.16$-1.07-8.4%
Next earningsThu, Nov 12·consensus EPS $-1.06

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.94$-41.0M
Q4 FY25$0———$-1.04$-39.4M
Q3 FY25$0———$-1.16$-32.9M
Q2 FY25$0———$-1.03$-34.8M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$11.3M$5.8M – $23.1M-$4.08-$4.30 – -$3.844
FY27$49.0M$36.9M – $61.1M-$3.85-$4.58 – -$3.124
FY28$358.8M$205.9M – $624.1M-$0.67-$4.18 – $3.325
FY29$999.7M$513.1M – $2.0B$5.61$2.06 – $13.192
FY30$1.6B$803.2M – $3.2B$9.41$3.46 – $22.162

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.87%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+72.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+144.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 57.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.045-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuySep 29Baker Bros. Advisors LpDirector33.7K sh$2.9MBuySep 28Baker Bros. Advisors LpDirector1.1M sh$95.4MSellJun 4John A. BorgesonCFO30.0K sh$1.0M
+ 10 other (8 awards · 2 exempts) in window

See when $KOD insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentSep 30SC 13D/A
8-KShareholder voteJun 48-K — Item 5.07: Shareholder vote
AI summary

Kodiak Sciences Inc. (KOD) disclosed the results of its annual meeting of shareholders in an 8-K filing under Item 5.07. Shareholders voted on an advisory say-on-pay resolution, ratification of the independent auditor. All management-sponsored proposals were approved by majority shareholder vote. Annual meeting results are a routine disclosure that confirms shareholder ratification of the board's composition and compensation practices.

+ 11 other (3 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

11 Stocks Most Likely to See a Short Squeeze Rallyschaeffersresearch.com·2d agoKodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026prnewswire.com·8d agoKodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Studymarketbeat.com·13d agoKodiak Sciences (NASDAQ:KOD) Director Bros. Advisors Lp Baker Acquires 33,726 Shares of Company Stockdefenseworld.net·14d agoA $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?247wallst.com·15d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · top 6 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport